Skip to main content

Market Overview

UPDATE: Morgan Stanley Reiterates On Charles River Laboratories Following CEO Conference Call


In a report published Tuesday, Morgan Stanley analyst Ricky R. Goldwasser reiterated an Equal-Weight rating on Charles River Laboratories (NYSE: CRL), but removed the $60.00 price target.

In the report, Morgan Stanley noted, “Pharma consolidation could driver near-term volatility but is factored in CRL's operating budget. While Large-scale pharma M&A, if it materializes, could translate to delays in project starts, CRL portfolio of services and diversified customer mix are in better position to weather the volatility than it was in prior merger waves. Mgmt also noted that revenues from biotech clients now exceed pharma's and pointed to an increasing mix of academic/govt. sales.

"Importantly, CRL's operating plan already assumes some level of pharma mergers. CEO views deals such as Novartis/GSK, which strengthen therapeutic areas as more thoughtful and beneficial to the CRO industry.”

Charles River Laboratories closed on Monday at $54.02.

Latest Ratings for CRL

Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Morgan StanleyMaintainsOverweight
Feb 2021Truist SecuritiesMaintainsBuy

View More Analyst Ratings for CRL
View the Latest Analyst Ratings


Related Articles (CRL)

View Comments and Join the Discussion!

Posted-In: Morgan Stanley Ricky R. GoldwasserAnalyst Color Price Target Analyst Ratings

Latest Ratings

GDWolfe ResearchDowngrades
QRTEAB of A SecuritiesInitiates Coverage On
ABB of A SecuritiesDowngrades42.0
VCTRB of A SecuritiesUpgrades32.0
BSIGB of A SecuritiesUpgrades27.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at